Penicillamine-induced proteinuria: risk factors

Area of Science:

• Nephrology
• Rheumatology
• Pharmacology

Background:

• Rheumatoid arthritis (RA) is a chronic autoimmune disease.
• Penicillamine is a disease-modifying antirheumatic drug (DMARD) used in RA treatment.
• Proteinuria is a potential adverse effect of penicillamine therapy.

Purpose of the Study:

• To investigate the incidence, characteristics, and risk factors of penicillamine-induced proteinuria in rheumatoid arthritis patients.
• To assess the reversibility of proteinuria and the possibility of continuing or restarting penicillamine therapy.

Main Methods:

• Retrospective analysis of 300 rheumatoid arthritis patients treated with penicillamine.
• Monitoring for proteinuria and renal function.
• Identification of risk factors including HLA types and prior gold therapy.

Main Results:

• Proteinuria developed in 9% of patients (26/300) at a mean dose of 591 mg/day and 9 months duration.
• Proteinuria resolved in all patients within a mean of 5.5 months.
• Twelve patients were successfully restarted or maintained on penicillamine with proteinuria resolution.
• HLA-B8, DR3, and prior gold-induced proteinuria were identified as risk factors.

Conclusions:

• Penicillamine-induced proteinuria in RA patients is generally reversible with no permanent renal impairment.
• Patients with prior gold-induced proteinuria require closer monitoring but can often continue or restart penicillamine.
• Tissue typing is not recommended due to the reversible nature of the proteinuria.